(August 19, 2024, 1:37 PM EDT) -- WASHINGTON, D.C. — A pharmaceutical wholesaler and related entities argue in their Aug. 16 U.S. Supreme Court brief that the court should not grant certiorari to review the Second Circuit U.S. Court of Appeals ruling affirming a district court’s dismissal of federal False Claims Act (FCA) suit alleging violations of the Anti-Kickback Statute (AKS), asserting the Second Circuit correctly held that the AKS is violated only when a defendant knows their conduct was unlawful....